Growth in the development of rare disease medicines has helped boost the number of new drugs approved in both the United States and the European Union.
Genomic data can have a significant effect on other areas of society. Insurance premiums, familial impact, identification. As we enter the genomic era, policy will need to reflect these new considerations.
The FDA have approved the first drug to treat women with advanced breast cancer caused by the same flawed gene that Angelina Jolie made famous.
How consumer genetic testing companies actually use your DNA is often less than clear and made more opaque through legal jargon and vagaries.
With drug development and other treatments, outcomes for the vast majority of diseases have improved over the past few decades, while life expectancy for sickle cell patients has declined.
The commissioner of the Food and Drug Administration questions whether the right financial incentives are in place for drugmakers who develop orphan drugs for rare diseases.
Last year, the pharma industry’ biggest trade group raised millions to change the conversation about drug pricing.
Companion DX is one of at least six clinical labs mired in bankruptcy court after Medicare alleged they improperly billed the government for unnecessary tests.
Project on Government Oversight says Amicus Therapeutics CEO John Crowley sent Gottlieb a friendly note just months before their drug was FDA fast-tracked.
The largest organisation of scientists who work in gene and cell therapy have come out against DIY gene therapies.
We caught up to Macrogen at ASHG, to speak about their latest CAP accreditation, and what benefits this will bring them in the next year.
Drugs reviewed by the FDA in programs intended to speed drug development were approved nearly a year quicker than drugs reviewed through normal processes.
Congress is working on a tax overhaul. But it turns out the tax bills in the House and Senate also aim to reshape health care.